Prophylactic Intravenous Nimodipine Treatment in Skull Base Surgery: Pharmacokinetic Aspects^[*]

 

 Buy Article Permissions and Reprints

Abstract

Background Nimodipine is primarily used in subarachnoid hemorrhage (SAH). Clinical trials revealed also a beneficial effect of prophylactic nimodipine treatment on cranial nerve functions following vestibular schwannoma surgery.

Objective The unknown pharmacokinetics of prophylactically administered nimodipine were investigated.

Methods Samples were taken from 27 patients with skull base lesions. Prophylactic intravenous nimodipine infusion was started 5.8–25.8 h (mean 17.9 h) before surgery. Nimodipine concentrations were determined in serum (intra- and postoperatively), cerebrospinal fluid (CSF) (intraoperatively), and tissue samples.

Results Wide interindividual differences were observed. Mean concentrations for nimodipine were 46.9 ng/ml (SD: 6.4; min. 4.1 and max. 92.7 ng/ml) in intraoperative serum, 73.2 ng/ml (SD: 16.7; min. 6.6 and max. 253 ng/ml) in postoperative serum and 8.3 ng/ml (SD: 1.5; min. 1.0 und max. 29.7 ng/ml) in intraoperative CSF. The correlation between intra- and postoperative serum (p=0.004, r=0.560) and between intra­operative serum and CSF concentration (p=0.003, r=0.567) were statistically significant. Furthermore the correlation between intraoperative serum concentration and concentrations collected from vestibular nerves was high (r=0.711), but not statistically significant (p=0.178).

Conclusions Interindividually, continously administered intravenous nimodipine produces considerably variable serum levels. Controls of nimodipine serum concentrations may be useful to optimize nimodipine medication in skull base surgery and in the management of SAH. The serum nimodipine level is a useful marker for CSF and intracranial nerve tissue concentrations of nimodipine.

^* This article was originally published online in Central European Neurosurgery on January 12, 2012 (DOI: 10.1055/s-0031-1291207)

• References

• 1 Tomassoni D, Lanari A, Silvestrelli G , et al. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 2008; 30: 744-766
  CrossrefPubMedGoogle Scholar
• 2 Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutical potential in cerebrovascular disease. Drugs 1989; 37: 669-699
  CrossrefPubMedGoogle Scholar
• 3 Allen GS, Ahn HS, Preziose TJ , et al. Cerebral arterial spasm – a controlled trail of nimodipine in patients with subarachnoid haemorrhage. N Engl J Med 1983; 308: 619-624
  CrossrefPubMedGoogle Scholar
• 4 Auer LM. Acute operation and preventive nimodipine improve outcome in patients with ruptured cerebral aneurysms. Neurosurgery 1984; 15: 57-66
  CrossrefPubMedGoogle Scholar
• 5 Ljunggren B, Brandt L, Säveland H , et al. Outcome in 60 consecutive patients treated with early aneurysm operation and intravenous nimodipine. J Neurosurg 1984; 61: 864-873
  CrossrefPubMedGoogle Scholar
• 6 Rinkel GJ, Feigin VL, Algra A , et al. Calcium antagonist for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2005; CD000277
  PubMedGoogle Scholar
• 7 Barker II FG, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid haemorrhage: a metaanalysis. J Neurosurg 1996; 84: 405-414
  CrossrefPubMedGoogle Scholar
• 8 Feigin VL, Rinkel GJ, Algra A , et al. Calcium antagonists in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Neurology 1998; 50: 876-883
  CrossrefPubMedGoogle Scholar
• 9 Pickard JD, Murray GD, Illingworth R , et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298: 636-642
  CrossrefPubMedGoogle Scholar
• 10 Soppi V, Kokki H, Koivisto T , et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage – a pilot study. Eur J Clin Pharmacol 2007; 63: 355-361
  CrossrefPubMedGoogle Scholar
• 11 Angelov DN, Neiss WF, Streppel M , et al. Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve. J Neurosci 1996; 16: 1041-1048
  PubMedGoogle Scholar
• 12 Bischoff B, Romstöck J, Fahlbusch R , et al. Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery. J Neurol Neurosurg Psychiatry 2008; 78: 170-175
  PubMedGoogle Scholar
• 13 Guntinas-Lichius O, Martinez-Portillo F, Lebek J , et al. Nimodipine maintains in vivo the increase of GFAP and enhances the astroglial ensheathment of surviving motoneurons in the rat following permanent target deprivation. J Neurocytol 1997; 26: 241-248
  CrossrefPubMedGoogle Scholar
• 14 Mattsson P, Aldskogius H, Svensson M. Nimodipine-induced improved survival rate of facial motor neurons following intracranial transection of the facial nerve in the adult rat. J Neurosurg 1999; 90: 760-765
  CrossrefPubMedGoogle Scholar
• 15 Mattsson P, Janson AM, Aldskogius H , et al. Nimodipine promotes regeneration and functional recovery after intracranial facial nerve crush. J Comp Neurol 2001; 437: 106-117
  CrossrefPubMedGoogle Scholar
• 16 Sekiya T, Yagihashi A, Asano K , et al. Nimodipine ameliorates trauma-induced cochlear neuronal death. Neurol Res 2002; 24: 775-780
  CrossrefPubMedGoogle Scholar
• 17 Scheller C, Strauss C, Fahlbusch R , et al. Delayed facial nerve paresis following acoustic neuroma resection and postoperative vasoactive treatment. Cent Eur Neurosurg 2004; 65: 103-107
  Article in Thieme ConnectPubMedGoogle Scholar
• 18 Scheller C, Richter HP, Engelhardt M , et al. Influence of prophylactic vasoactive treatment on cochlear and facial nerve functions following vestibular schwannoma surgery. A prospective and open-label randomized pilot study. Neurosurgery 2007; 61: 92-98
  CrossrefPubMedGoogle Scholar
• 19 Strauss C, Bischoff B, Neu M , et al. Vasoactive treatment for hearing preservation in acoustic neurinoma surgery. J Neurosurg 2001; 95: 771-777
  CrossrefPubMedGoogle Scholar
• 20 Strauss C, Romstöck J, Fahlbusch R , et al. Preservation of facial nerve function after postoperative vasoactive treatment in vestibular schwannoma surgery. Neurosurgery 2006; 59: 577-584
  CrossrefPubMedGoogle Scholar
• 21 Rämsch KD, Ahr G, Tettenborn D , et al. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid haemorrhage. Neurochirurgica 1985; 28 (Suppl. 01) 74-78
  PubMedGoogle Scholar
• 22 Vinge E, Andersson KE, Brandt L , et al. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol 1986; 30: 421-425
  CrossrefPubMedGoogle Scholar
• 23 Bach PR. Determination of nifedipine in serum or plasma by reversed-phase liquid chromatography. Clin Chem 1983; 29: 1344-1348
  PubMedGoogle Scholar
• 24 Krol GJ, Noe AJ, Yeh SC , et al. Gas and liquid chromatographic analyses of nimodipine calcium antagonist in blood plasma and cerebrospinal fluid. J Chromatogr 1984; 305: 105-118
  CrossrefPubMedGoogle Scholar
• 25 Nowychy MC, Fox A, Tsien RW. Three types of calcium channel with different calcium agonist sensitivity. Nature 1985; 316: 440-443
  CrossrefPubMedGoogle Scholar
• 26 Kazda S. Pharmacology of nimodipine, a calcium antagonist with preferential cerebrovascular activity. Neurochirurgia 1985; 28: 70-73
  PubMedGoogle Scholar
• 27 Towart R, Wehinger E, Meyer H , et al. The effects of nimodipine, its optical isomers and metabolites on isolated vascular smooth muscle. Arzneimittelforschung 1982; 32: 338-346
  PubMedGoogle Scholar
• 28 Alborch E, Salom JB, Torregrosa G. Calcium channel in cerebral arteries. Pharmacol Ther 1995; 68: 1-34
  CrossrefPubMedGoogle Scholar
• 29 Horn J, de Haan RJ, Vermeulen M , et al. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 2001; 32: 2433-2438
  CrossrefPubMedGoogle Scholar
• 30 Suwelack D, Weber H. Assessment of enterohepatic circulation of radioactivity following single dose of C14-nimodipine in the rat. Eur J Drug Metab Pharmacokinet 1985; 10: 231-239
  CrossrefPubMedGoogle Scholar
• 31 Gengo FM, Fagan SC, Krol G , et al. Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls. Br J Clin Pharmacol 1987; 23: 47-53
  CrossrefPubMedGoogle Scholar
• 32 Kirch W, Rämsch KD, Dührsen U , et al. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 1984; 4: 381-384
  PubMedGoogle Scholar
• 33 Mayberg MR, Batjer HH, Dacey R , et al. Guidelines for the management of aneurysmal subarachnoid haemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25: 2315-2328
  CrossrefPubMedGoogle Scholar
• 34 Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid haemorrhage. Current concepts. N Eng J Med 2006; 354: 387-396
  CrossrefPubMedGoogle Scholar